PCI Pharma Services has announced a footprint expansion program at its site in Tredegar, South Wales. This latest expansion demonstrates continued investment in PCI Pharma Services’ Tredegar facility.
This most recent expansion program in July of this year saw PCI Pharma Services acquire a further 26,500 square feet of additional footprint at Unit 6 Tafarnaubach Industrial Estate in Tredegar. This represented a continued expansion of its operations as a fully integrated service provider for the global healthcare industry. The new site will house a number of key departments to support the continued business growth, including offices and laboratories.
The Tredegar site expanded its capabilities in 2013 with the opening of a dedicated Contained Manufacturing Facility (CMF), specifically designed and built to enable the specialist processing of highly potent molecules into tablets and capsules utilizing contained technology. This investment resulted in global industry recognition when the site was awarded ISPE Facility of the Year in 2014, a highly prestigious award.
In 2014, PCI acquired Penn Pharma, adding drug manufacturing capability to its portfolio of services and PCI has continued its substantial investment in this specialization. The site undertook a further investment program increasing capacity of large scale commercial manufacturing capabilities by means of a single pot granulation process. In 2015, the site added additional granulation capabilities in the form of roller compaction technology providing a granulation technique for those products sensitive to heat and moisture. The Gerteis MiniPactor is also fully contained technology, further complimenting the site specialization for the development and manufacturing of highly potent molecules. 2016 saw continued investment in the form of contained Xcelodose® technology, providing a cost- and time-effective option for first in man studies.
Norman Barras, Managing Director, PCI Pharma Services Tredegar, commented: “I am delighted that we are continuing to grow and expand as a site. This additional footprint will ensure that we are even more able to meet the growth demands of our business and deliver excellence to each and every customer.”
Barras continued: “The site has benefited from significant investment over the last five or so years, delivering a center of excellence for manufacturing and uniquely positioning PCI Pharma Services within the global market place. This next phase of investment will help deliver a center of excellence for analytical services.”
Ken Richardson, Global Vice President, Engineering, PCI Pharma Services added: “With world-leading capabilities for the development and manufacturing of pharmaceutical products, this investment in and expansion of the Tredegar site will ensure that we continue to provide a truly integrated full-service solution to our clients. This additional footprint will assist in securing the growth potential for PCI Pharma Services moving forward.”